Trial Profile

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Patients With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Giredestrant (Primary) ; Dexamethasone; Exemestane; Fulvestrant; LHRH receptor agonists; Tamoxifen
Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
Focus Registrational; Therapeutic Use
Acronyms evERA Breast Cancer
Sponsors Genentech

15 Apr 2025 Planned End Date changed from 31 Mar 2026 to 15 Oct 2026.
15 Apr 2025 Planned primary completion date changed from 31 Mar 2026 to 15 Oct 2026.
16 Oct 2024 Planned primary completion date changed from 3 Oct 2024 to 31 Mar 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com